EQUIGEN is composed of two bioequivalency trials. The EQUIGEN Chronic Dose trial is comparing two disparate generics of lamotrigine. The EQUIGEN Single Dose trial is comparing brand lamotrigine with two disparate generics of lamotrigine for patients with epilepsy. The University of Cincinnati has contracted with the Johns Hopkins Brain Injury Outcomes team to serve as the Coordinating Center and the Kansas University Medical Center to serve as the Data Management Center for both trials.
The enrolling centers are:
University of Cincinnati: Michael Privitera, MD; Donna Schwieterman (513) 558-3975
University of Rochester: Michel Berg, MD; Diane Smith (585) 275-0404
University of Alabama at Birmingham: Jerzy Szaflarski, MD: Nancy Cohen (250) 934-7244
Brigham & Women’s Hospital (Boston): Barbara Dworetzky, MD; Nichelle Llewellyn (617) 732-5423
University of Pennsylvania: John Pollard, MD; Meryl Lozano (215) 662-7227
University of Iowa: A. LeBron Paige, MD; Jeri Sieren (319) 356-8744